NCT03571308View on ClinicalTrials.gov

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

January 2, 2020

Study Completion Date

August 31, 2023

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

R-CHOP + acalabrutinib

Patient will be given R-CHOP and acalabrutinib

Trial Locations (7)

SO16 6YD

Southampton University Hospitals NHS Tust, Southampton

LS9 7TF

St James's University Hospital, Leeds

NW12PG

University College London Hospitals, London

M204XB

The Christie NHS Foundation Trust, Manchester

NG51PB

Nottingham City Hospital Campus, Nottingham

OX37LE

Churchill Hospital, Oxford

PL68DH

Derriford Hospital, Plymouth

All Listed Sponsors
lead

University Hospital Southampton NHS Foundation Trust

OTHER

NCT03571308 - A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter